Molecular Diagnostics

In the Network Genomic Medicine (NGM) lung cancer hospitals and specialist practices across Germany work together to provide all lung cancer patients with a comprehensive molecular analysis of their tumor. The aim is to detect so-called driver mutations in your tumor tissue, which can be treated with targeted drugs.
Netzwerk Genomische Medizin (NGM) Lungenkrebs

For this purpose your physician requests the molecular diagnosis in the network’s headquarters at the University Hospital of Cologne. Once we have received the tumor tissue, it is examined for all molecular changes that might have therapeutic relevance for you, now or in the future. Within the network, we also try to offer our patients with a detected mutation, a suitable clinical trial using a new drug. Your doctor will inform you on changes found in your body, as well as on possible personalized therapeutic approaches.

Last update: 16. March 2016 , 15:25

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.
Share This